Wellness Clinical Research is recognizing Dr. Lucky Flores for his documented investigator credit in the HIBISCUS study group.
The research was published online in November 2021 and in the January 2022 issue of The Lancet Gastroenterology & Hepatology. This October 2026 WCR announcement highlights that earlier contribution.
Comparing approaches to induction treatment
HIBISCUS I and HIBISCUS II studied adults with moderately to severely active ulcerative colitis who had not previously received tumor necrosis factor inhibitors. The trials used comparable designs to evaluate etrolizumab alongside an active comparator and placebo.
The publication reported that etrolizumab met the primary comparison against placebo in HIBISCUS I, but not in HIBISCUS II. Pooled analyses did not demonstrate superiority to adalimumab. These findings contribute to the evidence base even when results differ between trials.
Investigator recognition grounded in the publication
PubMed includes the name Flores Lucky in the HIBISCUS study group collaborator list. WCR recognizes Dr. Flores for that documented investigator contribution.
This is an investigator credit associated with the trial program. The manuscript’s named authors are listed separately. WCR is recognizing the documented contribution without assigning a manuscript writing or presenting role.
Evidence from the full development process
Sponsors and CROs benefit from a clear view of investigator experience across studies with different designs and outcomes. Published results help inform future protocol development, study assessment, and clinical research planning.
Dr. Flores’s contribution forms part of his established involvement in inflammatory bowel disease research. WCR considers that experience together with the specific requirements of each new study.